A study by Karin suggests the potential of CXCL10 and CXCL9-based therapies to turn cold tumors into hot and enhance antitumor activity; however, future clinical trials are required to determine if any of these could be used for cancer immunotherapy either as monotherapy or combination with immune checkpoint inhibitors [168]. The gene discussed is CXCL10; the disease is cancer.